Aldoxorubicin – A New Approach to Cancer Treatment
Aldoxorubicin is a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor. Currently in late-stage clinical trials, aldoxorubicin appears to overcome the key limitations of doxorubicin, including cumulative dose restrictions. Aldoxorubicin utilizes an acid-sensitive linker that selectively binds to albumin, which may allow the cytotoxic payload to preferentially accumulate in the tumor and potentially spare the surrounding healthy tissue. This mechanism leverages the tumor's low pH environment, and accompanying dependency upon circulating albumin to fuel growth, to enable the delivery of multifold times the standard dosing of doxorubicin. In July 2017, CytRx out-licensed the worldwide rights to aldoxorubicin to NantCell, Inc.